A new industry commentary suggests that the cell therapy market—including gene, CAR-T and encapsulated cell approaches—is on track to grow from about $48.45 billion in 2024 to an estimated $403.86 billion by 2032, highlighting a large-scale shift from traditional treatments toward regenerative, curative therapies. The analysis notes that contract development and manufacturing organizations (CDMOs) now capture a majority of market share as the sector transitions from boutique R&D to scalable, GMP-compliant production infrastructure.
According to the report, expanded demand for viral vectors, cell-production platforms and delivery systems has helped overcome historic bottlenecks in manufacturing, enabling wider commercial access for treatments targeting a broad range of conditions. Key areas of opportunity cited include therapies for kidney disease, diabetes, central nervous system disorders and cardiovascular disease, with “off-the-shelf,” scalable cell products unlocking an estimated $44 billion segment within the broader regenerative medicine landscape.
Several companies are highlighted for their positioning within this transformation. Avant Technologies is advancing cell encapsulation approaches aimed at creating long-term insulin-producing cells for type 1 and insulin-dependent type 2 diabetes, potentially reducing immune-rejection challenges without chronic immunosuppression. ProKidney Corp. has presented Phase 2 data showing improved kidney function with its rilparencel cell therapy. Mesoblast continues to expand indications for its FDA-approved remestemcel-L cell product, and Lineage Cell Therapeutics remains engaged in production scale-up for multiple cell therapy candidates. A Phase 3b trial of NurOwn in amyotrophic lateral sclerosis has also received FDA clearance, reflecting broader clinical momentum in the field.
Proponents argue that advances in cell encapsulation, manufacturing scale, delivery systems and platform technology are accelerating the shift toward disease-modifying and potentially curative interventions across multiple therapeutic areas, positioning the regenerative medicine sector for rapid growth over the next decade.
